CD79A and malaria: Thus important differences in IgA half-life, IgA bio-distribution, and FcαRI expression profile between the transgenic mice and humans may have compromised the antibody's ability to mediate protective effects, and further experimentation will be required to fully dissect the role of IgA in human malaria.